maklogo
Market Research Report

Global Buprenorphine Transdermal Patches Market Insights, Size, and Forecast By End Use (Hospitals, Home Care, Rehabilitation Centers), By Application (Chronic Pain Management, Opioid Dependence Treatment, Acute Pain Management), By Dosage (5 mcg/hour, 10 mcg/hour, 20 mcg/hour, 30 mcg/hour), By Distribution Channel (Retail Pharmacies, Online Pharmacies, Hospital Pharmacies), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Key Companies, Competitive Analysis, Trends, and Projections for 2026-2035

Report ID:18493
Published Date:Jan 2026
No. of Pages:229
Base Year for Estimate:2025
Format:
Customize Report

Key Market Insights

Global Buprenorphine Transdermal Patches Market is projected to grow from USD 2.18 Billion in 2025 to USD 4.05 Billion by 2035, reflecting a compound annual growth rate of 6.4% from 2026 through 2035. This market encompasses the manufacturing, distribution, and sales of pharmaceutical patches designed to deliver buprenorphine transdermally, primarily for the treatment of moderate to severe chronic pain and opioid dependence. The market is driven by several factors, including the increasing prevalence of chronic pain conditions globally, a rising awareness and diagnosis of opioid use disorder, and a growing preference for non-invasive, long-acting drug delivery systems over traditional oral medications. The convenience and sustained release profile of transdermal patches enhance patient adherence and reduce the burden of frequent dosing. Additionally, the lower abuse potential of buprenorphine compared to full opioid agonists further contributes to its adoption, particularly in the context of the ongoing opioid crisis. However, market growth is tempered by factors such as the high cost associated with these advanced formulations and the potential for skin irritation or other adverse reactions at the application site. Regulatory hurdles and the stigma associated with opioid-based treatments, even for pain management, also pose challenges to market expansion.

Global Buprenorphine Transdermal Patches Market Value (USD Billion) Analysis, 2025-2035

maklogo
6.4%
CAGR from
2025 - 2035
Source:
www.makdatainsights.com

Important trends shaping the Buprenorphine Transdermal Patches Market include the development of innovative patch technologies aimed at improving drug absorption and reducing local adverse effects. There is a growing focus on once-weekly patches to further enhance patient convenience and compliance. Furthermore, the market is witnessing an increasing emphasis on product differentiation and strategic collaborations among key players to expand geographical reach and diversify product portfolios. Opportunities within this market largely lie in the underserved populations suffering from chronic pain in emerging economies and the development of buprenorphine patches specifically tailored for pediatric and geriatric populations, where precise dosing and ease of administration are critical. The expansion of telemedicine and home healthcare services also presents new avenues for the prescription and monitoring of buprenorphine transdermal patch therapy, particularly for patients with limited access to specialized care.

North America holds the dominant share in the Buprenorphine Transdermal Patches Market, primarily due to the high prevalence of chronic pain conditions, a well-established healthcare infrastructure, and significant awareness regarding opioid dependence treatment. Robust reimbursement policies and the presence of numerous key market players also contribute to its leading position. Conversely, the Asia Pacific region is anticipated to be the fastest growing market, propelled by improving healthcare access, increasing healthcare expenditure, and a rising awareness of pain management and opioid use disorder. The expanding geriatric population and the growing adoption of advanced pharmaceutical products in countries like China and India are also key drivers for this region's accelerated growth. Chronic pain management remains the leading application segment, reflecting the widespread need for effective and sustained pain relief. Key players such as Perrigo, Teva Pharmaceutical, Mylan, Zogenix, and Boehringer Ingelheim are strategically focusing on research and development to introduce new formulations, secure regulatory approvals, and expand their market presence through acquisitions and partnerships to maintain their competitive edge.

Quick Stats

  • Market Size (2025):

    USD 2.18 Billion

  • Projected Market Size (2035):

    USD 4.05 Billion

  • Leading Segment:

    Chronic Pain Management (88.5% Share)

  • Dominant Region (2025):

    North America (41.2% Share)

  • CAGR (2026-2035):

    6.4%

What is Buprenorphine Transdermal Patches?

Buprenorphine transdermal patches deliver the opioid partial agonist buprenorphine through the skin into the bloodstream. These patches provide continuous, slow release of the medication, bypassing the digestive system. They are primarily used for managing moderate to severe chronic pain that requires around the clock opioid treatment, and also in medication assisted treatment for opioid use disorder. The transdermal delivery offers consistent drug levels, improving pain control and potentially reducing the frequency of dosing compared to oral medications. This method aims for sustained therapeutic effects over several days, enhancing patient compliance and quality of life by minimizing peak and trough effects.

What are the Trends in Global Buprenorphine Transdermal Patches Market

  • The Rise of Telemedicine for Opioid Use Disorder Management

  • Optimizing Buprenorphine Delivery Beyond Transdermal Patches

  • Patient Centric Approaches in Long Acting Opioid Agonist Therapies

  • Expanding Access Buprenorphine Patches in Developing Regions

  • Integrating Mental Health Support with Buprenorphine Treatment

The Rise of Telemedicine for Opioid Use Disorder Management

The increasing accessibility of telemedicine is revolutionizing opioid use disorder management, particularly within the global buprenorphine transdermal patches market. Previously, geographical barriers and stigma often hindered individuals from accessing consistent care. Telemedicine platforms now bridge this gap, enabling remote consultations, prescription renewals, and ongoing support for patients utilizing these patches. This virtual care model offers unparalleled convenience and discretion, significantly improving treatment adherence and retention rates. For individuals in rural areas or those with mobility challenges, telemedicine ensures crucial access to prescribers and therapists, facilitating sustained recovery. This trend empowers patients with greater control over their treatment journey, fostering a more continuous and personalized approach to combating opioid dependence through buprenorphine transdermal patch therapy.

Optimizing Buprenorphine Delivery Beyond Transdermal Patches

The global buprenorphine market is witnessing a significant shift beyond traditional transdermal patches. While patches remain a staple, the industry is heavily investing in and adopting advanced delivery systems to enhance patient compliance, reduce misuse potential, and improve therapeutic outcomes. This optimization includes longer acting injectables, subdermal implants, and various oral formulations designed for extended release or sublingual absorption. These innovations aim to provide more consistent drug levels, decrease dosing frequency, and mitigate diversion risks associated with patch disposal. The trend reflects a broader move towards precision medicine and personalized treatment plans, offering healthcare providers a wider array of options to tailor buprenorphine therapy more effectively for patients with opioid use disorder and chronic pain.

What are the Key Drivers Shaping the Global Buprenorphine Transdermal Patches Market

  • Increasing Prevalence of Opioid Use Disorder (OUD) and Chronic Pain

  • Growing Awareness and Acceptance of Buprenorphine Transdermal Patches for OUD and Pain Management

  • Advancements in Transdermal Drug Delivery Technologies and Patch Formulations

  • Supportive Government Initiatives and Healthcare Policies Promoting OUD Treatment

  • Rising Demand for Non-Invasive and Convenient Drug Delivery Systems

Increasing Prevalence of Opioid Use Disorder (OUD) and Chronic Pain

The rising prevalence of opioid use disorder and chronic pain significantly fuels the global buprenorphine transdermal patches market. Opioid use disorder, a major public health crisis, necessitates effective and sustained treatment options like buprenorphine, which helps manage cravings and withdrawal symptoms. Concurrently, millions worldwide suffer from chronic pain conditions such as musculoskeletal pain, neuropathic pain, and cancer pain. For these patients, transdermal buprenorphine offers a valuable long acting, non invasive pain management solution with a lower abuse potential compared to full opioid agonists. The convenience and consistent drug delivery of patches improve patient adherence and quality of life, further driving their adoption by healthcare providers and patients seeking safer, more manageable therapies for these widespread health challenges.

Growing Awareness and Acceptance of Buprenorphine Transdermal Patches for OUD and Pain Management

Increasing understanding among healthcare providers and patients regarding the efficacy and benefits of buprenorphine transdermal patches is a key market driver. As the opioid crisis continues, there's a growing need for convenient and effective treatment options for both Opioid Use Disorder (OUD) and chronic pain. Buprenorphine patches offer a discreet, long acting, and non invasive alternative to daily oral medications, reducing the burden of frequent dosing and improving medication adherence. Educational initiatives and successful clinical outcomes are fueling this acceptance, leading to broader prescribing patterns and greater patient willingness to adopt this therapy. This shift in perception is expanding the patient pool for buprenorphine transdermal patches.

Advancements in Transdermal Drug Delivery Technologies and Patch Formulations

Improvements in transdermal drug delivery systems and patch designs are significantly propelling the buprenorphine transdermal patches market. Innovations focus on enhancing drug permeability across the skin, leading to more efficient and consistent buprenorphine absorption. This includes advancements in adhesive technologies for better skin adhesion and reduced irritation, ensuring patient comfort and compliance over extended wear periods. Furthermore, research into novel penetration enhancers and matrix formulations is optimizing drug release profiles, allowing for longer wear durations and reduced dosing frequency. These technological leaps translate into superior therapeutic outcomes for patients requiring sustained pain management or opioid dependence treatment, making patches a preferred and more effective delivery method.

Global Buprenorphine Transdermal Patches Market Restraints

Opioid Misuse Stigma and Reimbursement Challenges

Opioid misuse stigma significantly impedes buprenorphine transdermal patch adoption. Patients may hesitate to seek treatment due to perceived judgment from healthcare providers, pharmacists, or even family, fearing being labeled as "addicts." This societal stigma creates a barrier to both initial prescription and continued adherence. Simultaneously, reimbursement challenges compound the issue. Insurance coverage for buprenorphine patches varies widely, with many plans imposing stringent prior authorization requirements, high co-pays, or limited formularies. These financial hurdles disproportionately affect lower-income individuals and those without comprehensive insurance, making access to this effective treatment difficult. The combination of perceived social shame and practical cost barriers restricts wider market penetration and patient access to this crucial medication for opioid use disorder.

Availability of Alternative Buprenorphine Formulations and Treatment Modalities

The availability of alternative buprenorphine formulations and treatment modalities significantly restricts the growth of the global buprenorphine transdermal patches market. Patients and healthcare providers have numerous options beyond patches, including sublingual tablets, buccal films, and injectable sustained release formulations. These alternatives often offer varying dosing frequencies, administration routes, and patient preferences, which can make them more appealing in certain situations. For example, some patients may prefer the immediate effect of sublingual tablets or the convenience of less frequent injections, circumventing the need for daily patch application and removal. The ease of access and established use of these alternative forms mean that while transdermal patches offer specific benefits like sustained release and improved compliance, they face stiff competition from a diverse and mature landscape of other buprenorphine delivery systems.

Global Buprenorphine Transdermal Patches Market Opportunities

Global Expansion of Buprenorphine Transdermal Patches for Opioid Use Disorder & Chronic Pain Management

The global expansion of buprenorphine transdermal patches represents a substantial opportunity to address the critical needs of opioid use disorder and chronic pain management worldwide. These innovative patches offer sustained drug release, significantly improving patient compliance and reducing the misuse potential often associated with oral opioid treatments. For individuals battling opioid use disorder, they provide a discreet and effective maintenance therapy. Simultaneously, for chronic pain sufferers, patches deliver consistent relief, avoiding the peaks and troughs of intermittent dosing.

A key driver for this expansion lies in regions like Asia Pacific, which is experiencing rapid market growth, indicating a vast untapped patient population and increasing healthcare awareness. Expanding access to these patches enables healthcare systems to offer advanced, convenient, and less stigmatizing treatment options. The inherent advantages of transdermal delivery, including improved adherence and simplified administration, position these patches as a preferred choice. This global outreach facilitates better patient outcomes by widely disseminating a versatile therapeutic solution for two prevalent and challenging health conditions.

Innovation in Patient Adherence: Developing Enhanced Buprenorphine Transdermal Patch Formulations

The opportunity involves innovating buprenorphine transdermal patch formulations to significantly enhance patient adherence. Current patches, while effective, can face issues like limited wear duration, skin irritation, or inconsistent drug release, directly impacting patient compliance. Developing enhanced formulations means creating patches with improved adhesion, longer wear times, reduced skin sensitivities, or more stable and precise drug delivery. These advancements would directly lead to better patient outcomes for managing opioid dependence and chronic pain. This innovation is crucial for capturing new market share within the rapidly expanding global buprenorphine transdermal patches market, especially given the substantial growth observed in the Asia Pacific region. Prioritizing patient comfort and consistent therapeutic benefit will drive market penetration and improve overall treatment effectiveness.

Global Buprenorphine Transdermal Patches Market Segmentation Analysis

Key Market Segments

By Application

  • •Chronic Pain Management
  • •Opioid Dependence Treatment
  • •Acute Pain Management

By Dosage

  • •5 mcg/hour
  • •10 mcg/hour
  • •20 mcg/hour
  • •30 mcg/hour

By End Use

  • •Hospitals
  • •Home Care
  • •Rehabilitation Centers

By Distribution Channel

  • •Retail Pharmacies
  • •Online Pharmacies
  • •Hospital Pharmacies

Segment Share By Application

Share, By Application, 2025 (%)

  • Chronic Pain Management
  • Opioid Dependence Treatment
  • Acute Pain Management
maklogo
$2.18BGlobal Market Size, 2025
Source:
www.makdatainsights.com

Why is Chronic Pain Management dominating the Global Buprenorphine Transdermal Patches Market?

Chronic Pain Management commands the largest share due to the global prevalence of persistent pain conditions like neuropathic pain, lower back pain, and cancer pain. Buprenorphine patches offer sustained, around the clock analgesia, improving patient compliance and quality of life for individuals requiring long term pain control. Their extended wear time and favorable safety profile compared to other opioids make them a preferred therapeutic option in managing chronic discomfort effectively, reducing the burden of daily oral dosing and providing stable symptom relief.

What factors contribute to the prominence of Retail Pharmacies in the distribution of these patches?

Retail Pharmacies are a key distribution channel for buprenorphine transdermal patches because they offer widespread accessibility and convenience for patients with chronic conditions requiring regular medication refills. Their extensive network ensures easy access in urban and rural areas, facilitating consistent patient adherence to prescribed treatment regimens. The ease of prescription fulfillment and pharmacist counseling available at retail outlets further supports patient education and safe medication usage, solidifying their critical role in patient access to these essential pain management therapies.

How does the 10 mcg/hour dosage segment influence the Buprenorphine Transdermal Patches market?

The 10 mcg/hour dosage segment represents a significant portion of the market, serving as an optimal mid range option for many patients requiring moderate to severe chronic pain relief. This dosage often provides an effective balance between pain control and manageable side effects, making it a frequently prescribed starting point or maintenance dose for individuals transitioning from lower doses or those requiring more robust analgesia without escalating to higher strengths. Its versatility contributes significantly to patient customization and long term therapy adherence.

What Regulatory and Policy Factors Shape the Global Buprenorphine Transdermal Patches Market

Global Buprenorphine Transdermal Patches encounter a complex and evolving regulatory landscape. Major markets like the United States and European Union necessitate rigorous clinical trials and safety data for market authorization by agencies such as the FDA and EMA. Buprenorphine’s status as a controlled substance, typically Schedule III in the US and similar classifications internationally, imposes strict manufacturing, distribution, and prescribing controls.

Prescription monitoring programs are widespread, particularly in North America, aiming to mitigate opioid misuse and diversion risks. Reimbursement policies vary significantly by country and public or private healthcare systems, influencing market access and product uptake. Asia Pacific and Latin American regions present diverse regulatory maturity, with some countries adopting international standards while others possess more localized, less harmonized frameworks. Agencies worldwide increasingly prioritize real world evidence and post market surveillance. Evolving guidelines surrounding opioid prescribing for chronic pain, driven by public health concerns, continue to shape market dynamics globally. This necessitates manufacturers maintain stringent pharmacovigilance and adherence to evolving national and regional drug control acts.

What New Technologies are Shaping Global Buprenorphine Transdermal Patches Market?

The global buprenorphine transdermal patches market is experiencing dynamic innovation. Emerging technologies are significantly improving drug delivery and patient adherence. Microneedle array patches are gaining traction, promising more controlled and efficient absorption, which could enhance therapeutic outcomes and minimize systemic exposure variability. Developers are also exploring extended wear duration formulations, aiming to reduce application frequency and boost patient convenience. Smart patch technology, incorporating integrated sensors for real time drug release monitoring or physiological data capture, represents a future frontier for personalized pain management and addiction treatment. Furthermore, advancements in hypoallergenic adhesives and skin friendly materials are improving patch wearability and reducing skin irritation. These innovations collectively drive market expansion by offering superior efficacy, safety, and user experience.

Global Buprenorphine Transdermal Patches Market Regional Analysis

Global Buprenorphine Transdermal Patches Market

Trends, by Region

Largest Market
Fastest Growing Market
maklogo
41.2%

North America Market
Revenue Share, 2025

Source:
www.makdatainsights.com

Dominant Region

North America · 41.2% share

North America emerges as the dominant region in the global buprenorphine transdermal patches market, commanding a significant 41.2% market share. This robust performance is primarily driven by a well established healthcare infrastructure, high awareness and acceptance of advanced pain management solutions, and favorable reimbursement policies. The presence of key market players and continuous research and development initiatives further bolster the region's lead. Moreover, the increasing prevalence of chronic pain conditions and opioid use disorder contributes to the rising demand for effective and convenient treatment options like buprenorphine transdermal patches. Stringent regulatory frameworks ensuring product quality and efficacy also play a crucial role in maintaining market confidence and growth.

Fastest Growing Region

Asia Pacific · 9.2% CAGR

Asia Pacific is projected to be the fastest growing region in the global buprenorphine transdermal patches market, exhibiting an impressive CAGR of 9.2% from 2026 to 2035. This accelerated expansion is fueled by several key factors. Rising prevalence of opioid dependence across countries like China and India significantly drives demand. Enhanced healthcare infrastructure and increasing access to addiction treatment programs are also contributing. Furthermore, growing awareness among healthcare professionals regarding effective pain management and medication assisted treatment, coupled with favorable reimbursement policies in some nations, are bolstering market penetration. The convenience and sustained drug release offered by transdermal patches appeal to patients and providers alike, further cementing Asia Pacific's leadership in market growth.

Top Countries Overview

The US is a significant market for buprenorphine transdermal patches, driven by rising opioid dependence and demand for abuse-deterrent formulations. It holds a substantial share of the global market, with key pharmaceutical companies focusing on product innovation and expanding access. Regulatory approvals and physician prescribing patterns play a crucial role in shaping its growth and the competitive landscape.

China is a key player in the global buprenorphine transdermal patches market, driven by its large patient population and increasing demand for pain management. Domestic manufacturers are expanding, while international firms seek market entry. Regulatory landscape and healthcare policies significantly influence market dynamics, with a growing focus on local production and wider access to pain relief solutions.

India is emerging as a significant player in the global buprenorphine transdermal patches market. The country's growing healthcare infrastructure, increasing awareness of opioid dependence treatment, and rising disposable incomes are driving demand. Domestic manufacturers are scaling up production, leveraging cost advantages and expanding distribution networks. India's strong pharmaceutical manufacturing capabilities and potential for medical tourism further position it as a key market contributor and innovator.

Impact of Geopolitical and Macroeconomic Factors

Geopolitical stability in key manufacturing regions and international trade relations significantly impact the supply chain for active pharmaceutical ingredients (APIs) and finished products. Political conflicts and trade disputes can disrupt raw material availability and increase transportation costs, affecting market competitiveness. Regulatory harmonization or divergence across different countries influences market access and product approval timelines, with stringent regulations in developed economies often acting as a barrier to entry. Furthermore, government healthcare policies and reimbursement frameworks for opioid dependence treatments directly shape market demand and product affordability.

Macroeconomic conditions, particularly disposable income levels and healthcare spending, dictate patient access and market growth. Economic recessions can lead to reduced healthcare budgets and patient ability to afford treatment, potentially shifting demand towards more cost effective alternatives. Inflationary pressures can increase manufacturing and operational costs for pharmaceutical companies, impacting profitability and potentially leading to price adjustments. Currency fluctuations between major trading blocs also affect import export dynamics and the ultimate pricing of buprenorphine transdermal patches in different markets.

Recent Developments

  • March 2025

    Perrigo announced the acquisition of a European-based specialty pharmaceutical company with a strong pipeline in pain management. This strategic move is expected to significantly bolster Perrigo's presence in the generic buprenorphine transdermal patches market across key European regions.

  • July 2024

    Teva Pharmaceutical launched a new, higher-dose buprenorphine transdermal patch formulation in several major markets, including the US and EU. This product aims to address the needs of patients requiring more potent opioid dependence treatment options, expanding Teva's market share in this segment.

  • September 2025

    Mylan entered into a strategic partnership with a leading telemedicine provider to enhance access to buprenorphine transdermal patch prescriptions and patient support services. This initiative aims to improve treatment adherence and reach underserved populations, particularly in rural areas.

  • November 2024

    Sandoz received FDA approval for its generic version of a prominent branded buprenorphine transdermal patch, marking a significant step for increasing affordability and accessibility. This launch is expected to intensify competition and potentially drive down prices within the market.

  • February 2025

    Zogenix announced a research and development collaboration with a biotechnology firm specializing in novel drug delivery systems to explore enhanced buprenorphine patch technologies. This partnership aims to develop next-generation patches with improved efficacy, reduced side effects, and extended wear time.

Key Players Analysis

Perrigo and Teva Pharmaceutical lead the global buprenorphine transdermal patches market with strong generic portfolios and established distribution. Mylan and Sandoz are also significant players, actively expanding their market share through cost effective generics. Zogenix and Boehringer Ingelheim, while not primary patch manufacturers, contribute through upstream active pharmaceutical ingredient supply or related opioid dependence treatments, highlighting the interconnectedness of the market. Strategic initiatives include enhancing patch adherence and reducing abuse potential, driving demand for innovative transdermal delivery systems. Market growth is further propelled by the rising prevalence of opioid use disorder and increasing awareness of medication assisted treatment options.

List of Key Companies:

  1. Perrigo
  2. Teva Pharmaceutical
  3. Mylan
  4. Zogenix
  5. Boehringer Ingelheim
  6. Sandoz
  7. Hikma Pharmaceuticals
  8. Fresenius Kabi
  9. Amgen
  10. Egalet
  11. Purdue Pharma
  12. Johnson & Johnson
  13. Alvogen
  14. Kremers Urban
  15. Mallinckrodt Pharmaceuticals

Report Scope and Segmentation

Report ComponentDescription
Market Size (2025)USD 2.18 Billion
Forecast Value (2035)USD 4.05 Billion
CAGR (2026-2035)6.4%
Base Year2025
Historical Period2020-2025
Forecast Period2026-2035
Segments Covered
  • By Application:
    • •Chronic Pain Management
    • •Opioid Dependence Treatment
    • •Acute Pain Management
  • By Dosage:
    • •5 mcg/hour
    • •10 mcg/hour
    • •20 mcg/hour
    • •30 mcg/hour
  • By End Use:
    • •Hospitals
    • •Home Care
    • •Rehabilitation Centers
  • By Distribution Channel:
    • •Retail Pharmacies
    • •Online Pharmacies
    • •Hospital Pharmacies
Regional Analysis
  • North America
  • • United States
  • • Canada
  • Europe
  • • Germany
  • • France
  • • United Kingdom
  • • Spain
  • • Italy
  • • Russia
  • • Rest of Europe
  • Asia-Pacific
  • • China
  • • India
  • • Japan
  • • South Korea
  • • New Zealand
  • • Singapore
  • • Vietnam
  • • Indonesia
  • • Rest of Asia-Pacific
  • Latin America
  • • Brazil
  • • Mexico
  • • Rest of Latin America
  • Middle East and Africa
  • • South Africa
  • • Saudi Arabia
  • • UAE
  • • Rest of Middle East and Africa

Table of Contents:

1. Introduction
1.1. Objectives of Research
1.2. Market Definition
1.3. Market Scope
1.4. Research Methodology
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends
4. Market Factor Analysis
4.1. Porter's Five Forces Model Analysis
4.1.1. Rivalry among Existing Competitors
4.1.2. Bargaining Power of Buyers
4.1.3. Bargaining Power of Suppliers
4.1.4. Threat of Substitute Products or Services
4.1.5. Threat of New Entrants
4.2. PESTEL Analysis
4.2.1. Political Factors
4.2.2. Economic & Social Factors
4.2.3. Technological Factors
4.2.4. Environmental Factors
4.2.5. Legal Factors
4.3. Supply and Value Chain Assessment
4.4. Regulatory and Policy Environment Review
4.5. Market Investment Attractiveness Index
4.6. Technological Innovation and Advancement Review
4.7. Impact of Geopolitical and Macroeconomic Factors
4.8. Trade Dynamics: Import-Export Assessment (Where Applicable)
5. Global Buprenorphine Transdermal Patches Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
5.1. Market Analysis, Insights and Forecast, 2020-2035, By Application
5.1.1. Chronic Pain Management
5.1.2. Opioid Dependence Treatment
5.1.3. Acute Pain Management
5.2. Market Analysis, Insights and Forecast, 2020-2035, By Dosage
5.2.1. 5 mcg/hour
5.2.2. 10 mcg/hour
5.2.3. 20 mcg/hour
5.2.4. 30 mcg/hour
5.3. Market Analysis, Insights and Forecast, 2020-2035, By End Use
5.3.1. Hospitals
5.3.2. Home Care
5.3.3. Rehabilitation Centers
5.4. Market Analysis, Insights and Forecast, 2020-2035, By Distribution Channel
5.4.1. Retail Pharmacies
5.4.2. Online Pharmacies
5.4.3. Hospital Pharmacies
5.5. Market Analysis, Insights and Forecast, 2020-2035, By Region
5.5.1. North America
5.5.2. Europe
5.5.3. Asia-Pacific
5.5.4. Latin America
5.5.5. Middle East and Africa
6. North America Buprenorphine Transdermal Patches Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
6.1. Market Analysis, Insights and Forecast, 2020-2035, By Application
6.1.1. Chronic Pain Management
6.1.2. Opioid Dependence Treatment
6.1.3. Acute Pain Management
6.2. Market Analysis, Insights and Forecast, 2020-2035, By Dosage
6.2.1. 5 mcg/hour
6.2.2. 10 mcg/hour
6.2.3. 20 mcg/hour
6.2.4. 30 mcg/hour
6.3. Market Analysis, Insights and Forecast, 2020-2035, By End Use
6.3.1. Hospitals
6.3.2. Home Care
6.3.3. Rehabilitation Centers
6.4. Market Analysis, Insights and Forecast, 2020-2035, By Distribution Channel
6.4.1. Retail Pharmacies
6.4.2. Online Pharmacies
6.4.3. Hospital Pharmacies
6.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
6.5.1. United States
6.5.2. Canada
7. Europe Buprenorphine Transdermal Patches Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
7.1. Market Analysis, Insights and Forecast, 2020-2035, By Application
7.1.1. Chronic Pain Management
7.1.2. Opioid Dependence Treatment
7.1.3. Acute Pain Management
7.2. Market Analysis, Insights and Forecast, 2020-2035, By Dosage
7.2.1. 5 mcg/hour
7.2.2. 10 mcg/hour
7.2.3. 20 mcg/hour
7.2.4. 30 mcg/hour
7.3. Market Analysis, Insights and Forecast, 2020-2035, By End Use
7.3.1. Hospitals
7.3.2. Home Care
7.3.3. Rehabilitation Centers
7.4. Market Analysis, Insights and Forecast, 2020-2035, By Distribution Channel
7.4.1. Retail Pharmacies
7.4.2. Online Pharmacies
7.4.3. Hospital Pharmacies
7.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
7.5.1. Germany
7.5.2. France
7.5.3. United Kingdom
7.5.4. Spain
7.5.5. Italy
7.5.6. Russia
7.5.7. Rest of Europe
8. Asia-Pacific Buprenorphine Transdermal Patches Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
8.1. Market Analysis, Insights and Forecast, 2020-2035, By Application
8.1.1. Chronic Pain Management
8.1.2. Opioid Dependence Treatment
8.1.3. Acute Pain Management
8.2. Market Analysis, Insights and Forecast, 2020-2035, By Dosage
8.2.1. 5 mcg/hour
8.2.2. 10 mcg/hour
8.2.3. 20 mcg/hour
8.2.4. 30 mcg/hour
8.3. Market Analysis, Insights and Forecast, 2020-2035, By End Use
8.3.1. Hospitals
8.3.2. Home Care
8.3.3. Rehabilitation Centers
8.4. Market Analysis, Insights and Forecast, 2020-2035, By Distribution Channel
8.4.1. Retail Pharmacies
8.4.2. Online Pharmacies
8.4.3. Hospital Pharmacies
8.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
8.5.1. China
8.5.2. India
8.5.3. Japan
8.5.4. South Korea
8.5.5. New Zealand
8.5.6. Singapore
8.5.7. Vietnam
8.5.8. Indonesia
8.5.9. Rest of Asia-Pacific
9. Latin America Buprenorphine Transdermal Patches Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
9.1. Market Analysis, Insights and Forecast, 2020-2035, By Application
9.1.1. Chronic Pain Management
9.1.2. Opioid Dependence Treatment
9.1.3. Acute Pain Management
9.2. Market Analysis, Insights and Forecast, 2020-2035, By Dosage
9.2.1. 5 mcg/hour
9.2.2. 10 mcg/hour
9.2.3. 20 mcg/hour
9.2.4. 30 mcg/hour
9.3. Market Analysis, Insights and Forecast, 2020-2035, By End Use
9.3.1. Hospitals
9.3.2. Home Care
9.3.3. Rehabilitation Centers
9.4. Market Analysis, Insights and Forecast, 2020-2035, By Distribution Channel
9.4.1. Retail Pharmacies
9.4.2. Online Pharmacies
9.4.3. Hospital Pharmacies
9.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of Latin America
10. Middle East and Africa Buprenorphine Transdermal Patches Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
10.1. Market Analysis, Insights and Forecast, 2020-2035, By Application
10.1.1. Chronic Pain Management
10.1.2. Opioid Dependence Treatment
10.1.3. Acute Pain Management
10.2. Market Analysis, Insights and Forecast, 2020-2035, By Dosage
10.2.1. 5 mcg/hour
10.2.2. 10 mcg/hour
10.2.3. 20 mcg/hour
10.2.4. 30 mcg/hour
10.3. Market Analysis, Insights and Forecast, 2020-2035, By End Use
10.3.1. Hospitals
10.3.2. Home Care
10.3.3. Rehabilitation Centers
10.4. Market Analysis, Insights and Forecast, 2020-2035, By Distribution Channel
10.4.1. Retail Pharmacies
10.4.2. Online Pharmacies
10.4.3. Hospital Pharmacies
10.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
10.5.1. South Africa
10.5.2. Saudi Arabia
10.5.3. UAE
10.5.4. Rest of Middle East and Africa
11. Competitive Analysis and Company Profiles
11.1. Market Share of Key Players
11.1.1. Global Company Market Share
11.1.2. Regional/Sub-Regional Company Market Share
11.2. Company Profiles
11.2.1. Perrigo
11.2.1.1. Business Overview
11.2.1.2. Products Offering
11.2.1.3. Financial Insights (Based on Availability)
11.2.1.4. Company Market Share Analysis
11.2.1.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.1.6. Strategy
11.2.1.7. SWOT Analysis
11.2.2. Teva Pharmaceutical
11.2.2.1. Business Overview
11.2.2.2. Products Offering
11.2.2.3. Financial Insights (Based on Availability)
11.2.2.4. Company Market Share Analysis
11.2.2.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.2.6. Strategy
11.2.2.7. SWOT Analysis
11.2.3. Mylan
11.2.3.1. Business Overview
11.2.3.2. Products Offering
11.2.3.3. Financial Insights (Based on Availability)
11.2.3.4. Company Market Share Analysis
11.2.3.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.3.6. Strategy
11.2.3.7. SWOT Analysis
11.2.4. Zogenix
11.2.4.1. Business Overview
11.2.4.2. Products Offering
11.2.4.3. Financial Insights (Based on Availability)
11.2.4.4. Company Market Share Analysis
11.2.4.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.4.6. Strategy
11.2.4.7. SWOT Analysis
11.2.5. Boehringer Ingelheim
11.2.5.1. Business Overview
11.2.5.2. Products Offering
11.2.5.3. Financial Insights (Based on Availability)
11.2.5.4. Company Market Share Analysis
11.2.5.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.5.6. Strategy
11.2.5.7. SWOT Analysis
11.2.6. Sandoz
11.2.6.1. Business Overview
11.2.6.2. Products Offering
11.2.6.3. Financial Insights (Based on Availability)
11.2.6.4. Company Market Share Analysis
11.2.6.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.6.6. Strategy
11.2.6.7. SWOT Analysis
11.2.7. Hikma Pharmaceuticals
11.2.7.1. Business Overview
11.2.7.2. Products Offering
11.2.7.3. Financial Insights (Based on Availability)
11.2.7.4. Company Market Share Analysis
11.2.7.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.7.6. Strategy
11.2.7.7. SWOT Analysis
11.2.8. Fresenius Kabi
11.2.8.1. Business Overview
11.2.8.2. Products Offering
11.2.8.3. Financial Insights (Based on Availability)
11.2.8.4. Company Market Share Analysis
11.2.8.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.8.6. Strategy
11.2.8.7. SWOT Analysis
11.2.9. Amgen
11.2.9.1. Business Overview
11.2.9.2. Products Offering
11.2.9.3. Financial Insights (Based on Availability)
11.2.9.4. Company Market Share Analysis
11.2.9.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.9.6. Strategy
11.2.9.7. SWOT Analysis
11.2.10. Egalet
11.2.10.1. Business Overview
11.2.10.2. Products Offering
11.2.10.3. Financial Insights (Based on Availability)
11.2.10.4. Company Market Share Analysis
11.2.10.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.10.6. Strategy
11.2.10.7. SWOT Analysis
11.2.11. Purdue Pharma
11.2.11.1. Business Overview
11.2.11.2. Products Offering
11.2.11.3. Financial Insights (Based on Availability)
11.2.11.4. Company Market Share Analysis
11.2.11.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.11.6. Strategy
11.2.11.7. SWOT Analysis
11.2.12. Johnson & Johnson
11.2.12.1. Business Overview
11.2.12.2. Products Offering
11.2.12.3. Financial Insights (Based on Availability)
11.2.12.4. Company Market Share Analysis
11.2.12.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.12.6. Strategy
11.2.12.7. SWOT Analysis
11.2.13. Alvogen
11.2.13.1. Business Overview
11.2.13.2. Products Offering
11.2.13.3. Financial Insights (Based on Availability)
11.2.13.4. Company Market Share Analysis
11.2.13.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.13.6. Strategy
11.2.13.7. SWOT Analysis
11.2.14. Kremers Urban
11.2.14.1. Business Overview
11.2.14.2. Products Offering
11.2.14.3. Financial Insights (Based on Availability)
11.2.14.4. Company Market Share Analysis
11.2.14.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.14.6. Strategy
11.2.14.7. SWOT Analysis
11.2.15. Mallinckrodt Pharmaceuticals
11.2.15.1. Business Overview
11.2.15.2. Products Offering
11.2.15.3. Financial Insights (Based on Availability)
11.2.15.4. Company Market Share Analysis
11.2.15.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.15.6. Strategy
11.2.15.7. SWOT Analysis

List of Figures

List of Tables

Table 1: Global Buprenorphine Transdermal Patches Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 2: Global Buprenorphine Transdermal Patches Market Revenue (USD billion) Forecast, by Dosage, 2020-2035

Table 3: Global Buprenorphine Transdermal Patches Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 4: Global Buprenorphine Transdermal Patches Market Revenue (USD billion) Forecast, by Distribution Channel, 2020-2035

Table 5: Global Buprenorphine Transdermal Patches Market Revenue (USD billion) Forecast, by Region, 2020-2035

Table 6: North America Buprenorphine Transdermal Patches Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 7: North America Buprenorphine Transdermal Patches Market Revenue (USD billion) Forecast, by Dosage, 2020-2035

Table 8: North America Buprenorphine Transdermal Patches Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 9: North America Buprenorphine Transdermal Patches Market Revenue (USD billion) Forecast, by Distribution Channel, 2020-2035

Table 10: North America Buprenorphine Transdermal Patches Market Revenue (USD billion) Forecast, by Country, 2020-2035

Table 11: Europe Buprenorphine Transdermal Patches Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 12: Europe Buprenorphine Transdermal Patches Market Revenue (USD billion) Forecast, by Dosage, 2020-2035

Table 13: Europe Buprenorphine Transdermal Patches Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 14: Europe Buprenorphine Transdermal Patches Market Revenue (USD billion) Forecast, by Distribution Channel, 2020-2035

Table 15: Europe Buprenorphine Transdermal Patches Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 16: Asia Pacific Buprenorphine Transdermal Patches Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 17: Asia Pacific Buprenorphine Transdermal Patches Market Revenue (USD billion) Forecast, by Dosage, 2020-2035

Table 18: Asia Pacific Buprenorphine Transdermal Patches Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 19: Asia Pacific Buprenorphine Transdermal Patches Market Revenue (USD billion) Forecast, by Distribution Channel, 2020-2035

Table 20: Asia Pacific Buprenorphine Transdermal Patches Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 21: Latin America Buprenorphine Transdermal Patches Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 22: Latin America Buprenorphine Transdermal Patches Market Revenue (USD billion) Forecast, by Dosage, 2020-2035

Table 23: Latin America Buprenorphine Transdermal Patches Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 24: Latin America Buprenorphine Transdermal Patches Market Revenue (USD billion) Forecast, by Distribution Channel, 2020-2035

Table 25: Latin America Buprenorphine Transdermal Patches Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 26: Middle East & Africa Buprenorphine Transdermal Patches Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 27: Middle East & Africa Buprenorphine Transdermal Patches Market Revenue (USD billion) Forecast, by Dosage, 2020-2035

Table 28: Middle East & Africa Buprenorphine Transdermal Patches Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 29: Middle East & Africa Buprenorphine Transdermal Patches Market Revenue (USD billion) Forecast, by Distribution Channel, 2020-2035

Table 30: Middle East & Africa Buprenorphine Transdermal Patches Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Frequently Asked Questions

Industry

Healthcare Market Research

Explore comprehensive market research reports covering all aspects of the Healthcare industry, including market size, growth trends, competitive landscape, and strategic insights.

View Industry Page
;